Geron Corp - Company Profile
Powered by
All the data and insights you need on Geron Corp in one report.
- Save hours of research time and resources with
our up-to-date Geron Corp Strategy Report
- Understand Geron Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Geron Corp (Geron) is a late-stage clinical biopharmaceutical company that focuses on the development and commercialization of imetelstat, a first-in-class telomerase inhibitor in hematologic myeloid malignancies. It’s clinical studies include IMerge, a Phase 2 trial in lower risk myelodysplastic syndromes; and IMbark, a Phase 2 clinical trial in intermediate or high-risk myelofibrosis. Imetelstat received Fast Track designation from the US FDA to treat patients with transfusion-dependent anemia due to lower or intermediate-risk myelodysplastic syndromes (MDS) and patients with intermediate or high-risk myelofibrosis (MF). The company utilizes core expertise in telomerase and telomere biology and its proprietary nucleic acid chemistry for the development of imetelstat. Geron is headquartered in Menlo Park, California, the US.
Geron Corp premium industry data and analytics
Products and Services
Products |
---|
Pipeline |
Imetelstat-Telomerase Inhibitor |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Official Trials/Tests | In April, the company announced positive top-line results of its product Imetelstat from IMerge Phase 3 Trial. |
2021 | Official Trials/Tests | In October, the company announced the completion of patient enrollment in IMerge Phase 3 Clinical Trial in Myelodysplastic Syndromes. |
2021 | Contracts/Agreements | In October, the company’s Imetelstat entered into New Innovative Licensing and Access Pathway in United Kingdom. |
Competitor Comparison
Key Parameters | Geron Corp | Amgen Inc | Genmab AS | FibroGen Inc | Acceleron Pharma Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | Denmark | United States of America | United States of America |
City | Foster City | Thousand Oaks | Koebenhavn V | San Francisco | Cambridge |
State/Province | California | California | - | California | Massachusetts |
No. of Employees | 141 | 26,700 | 2,204 | 486 | 312 |
Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
John A. Scarlett, M.D. | President; Chairman; Director; Chief Executive Officer | Executive Board | 2018 | 72 |
Michelle Robertson | Treasurer; Executive Vice President; Chief Financial Officer | Senior Management | 2023 | - |
Andrew J. Grethlein, Ph.D. | Chief Operating Officer; Executive Vice President | Senior Management | 2019 | 58 |
Stephen N. Rosenfield | Secretary; Chief Legal Officer; Executive Vice President | Senior Management | 2019 | 73 |
Faye Feller, M.D | Executive Vice President; Chief Medical Officer | Senior Management | 2022 | 40 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward